About CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 2
CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 2 (ST3GAL2) is a protein
from Homo sapiens identified by UniProt accession
Q16842, 350 residues long.
MolForge cross-references it against 0 known binders and
97 disease associations.
Target properties
| Protein name | CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 2 |
| UniProt accession | Q16842 |
| Gene | ST3GAL2 |
| Organism | Homo sapiens |
| Length | 350 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (97)
Diseases linked to this target (Open Targets).
- COVID-19 · score 0.46
- severe acute respiratory syndrome · score 0.37
- haptoglobin measurement · score 0.32
- lung adenocarcinoma · score 0.19
- body height · score 0.17
- body mass index · score 0.16
- endometrial cancer · score 0.10
- breast adenocarcinoma · score 0.10
- gastric adenocarcinoma · score 0.10
- amino acid measurement · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q16842-F1 | alphafold | PREDICTED | 85.43 | — |
Amino-acid sequence (350 residues)
MKCSLRVWFL SVAFLLVFIM SLLFTYSHHS MATLPYLDSG ALDGTHRVKL VPGYAGLQRL SKERLSGKSC ACRRCMGDAG ASDWFDSHFD GNISPVWTRE NMDLPPDVQR WWMMLQPQFK SHNTNEVLEK LFQIVPGENP YRFRDPHQCR RCAVVGNSGN LRGSGYGQDV DGHNFIMRMN QAPTVGFEQD VGSRTTHHFM YPESAKNLPA NVSFVLVPFK VLDLLWIASA LSTGQIRFTY APVKSFLRVD KEKVQIYNPA FFKYIHDRWT EHHGRYPSTG MLVLFFALHV CDEVNVYGFG ADSRGNWHHY WENNRYAGEF RKTGVHDADF EAHIIDMLAK ASKIEVYRGN
Explore CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets